Schonfeld Strategic Advisors LLC Leap Therapeutics, Inc. Transaction History

Schonfeld Strategic Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.29 - $0.72 $696 - $1,728	-2,400 Reduced 4.52%	50,700 $17,000
Q4 2022 Feb 14, 2023	BUY	$0.42 - $9.18 $420 - $9,180	1,000 Added 1.92%	53,100 $23,000
Q3 2022 Nov 14, 2022	BUY	$0.92 - $9.3 $92 - $930	100 Added 0.19%	52,100 $46,000
Q2 2022 Aug 15, 2022	BUY	$0.96 - $1.91 $2,688 - $5,348	2,800 Added 5.69%	52,000 $60,000
Q1 2022 May 16, 2022	BUY	$1.6 - $3.35 $22,240 - $46,565	13,900 Added 39.38%	49,200 $87,000
Q3 2021 Nov 16, 2021	BUY	$1.35 - $4.01 $47,655 - $141,553	35,300 New	35,300 $142,000
Q3 2020 Nov 16, 2020	SELL	$1.68 - $2.17 $670,887 - $866,563	-399,338 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.39 - $2.84 $555,079 - $1.13 Million	399,338 New	399,338 $835,000
Q1 2020 May 15, 2020	SELL	$1.06 - $2.94 $85,138 - $236,137	-80,319 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$0.63 - $1.37 $2,079 - $4,521	3,300 Added 4.28%	80,319 $90,000
Q3 2019 Nov 14, 2019	BUY	$1.17 - $2.36 $90,112 - $181,764	77,019 New	77,019 $90,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $275M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.